Nanna Therapeutics is a small-molecule focused therapeutics biotech brand that specializes in the research and development of transformative medicines for mitochondrial and rare diseases. As a subsidiary of Astellas, a global pharmaceutical company, Nanna Therapeutics works alongside Mitobridge, forming the Mitobridge Division. With a strong focus on mitochondria, the energy source of cells, Nanna Therapeutics targets the underlying causes of various diseases, including life-limiting mitochondrial diseases that currently lack effective treatments.

The brand's approach involves leveraging enabling platforms to develop innovative therapeutics through phenotypic screening and optimization approaches. By combining expertise in mitochondrial biology and immune-modulation, along with a unique patient cell-enabled screening paradigm, Nanna Therapeutics identifies disease-related changes in mitochondrial function to deliver new medicines. Nanna Therapeutics collaborates closely with external partners, including universities, academic institutions, and centers of excellence for mitochondria research.

They also work closely with Mitobridge in Cambridge, MA, and Astellas colleagues in Japan and elsewhere. With an experienced and dynamic team of scientists and leaders, Nanna Therapeutics is dedicated to delivering life-changing medicines to patients